Founded in 2014, AnnJi Pharmaceutical specializes in developing small molecules for rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, with a focus on creating global collaborations and business partnerships for late-stage product development and commercialization. The company is dedicated to developing first-in-class small molecules that address unmet medical needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, with the goal of translating and developing unique, innovative, and highly differentiated drug therapies.